SOX2-OT and cancer: For studies evaluating OS in different type of cancer, the results suggested that promoted SOX2OT levels could estimate worse outcome in gastric cancer (HR = 2.30, 95% CI: 1.52–3.47, P<0.0001) (Fig 4A).